Akèy › Enfeksyon Adenoviridae
Etid klinik pou Enfeksyon Adenoviridae ap rekrite nan Etazini
16 etid pou Enfeksyon Adenoviridae ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Columbus, OH5 etid
- Washington, DC4 etid
- Cincinnati, OH4 etid
- New York City, NY3 etid
- Milwaukee, WI3 etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Ap rekriteEtid obsèvasyon
Laj 2 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT01011712Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
Ap rekriteFaz 1 bonèVolontè an sante akeyi
Laj 1 a 85 · Tout sèks · Mizajou Sep 24, 2026 · NCT03665675Viral Infections in Healthy and Immunocompromised Hosts
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
6 Months – 120 Years · Tout sèks · Mizajou Sep 14, 2026 · NCT01306084Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone
Ap rekriteFaz 3
1 Day – 30 Years · Tout sèks · Mizajou Sep 11, 2026 · NCT07225972Donor-Derived Viral Specific T-cells (VSTs)
Ap rekriteFaz 1/2
4 Weeks · Tout sèks · Mizajou Sep 4, 2026 · NCT02048332Third Party Viral Specific T-cells (VSTs)
Ap rekriteFaz 2
2 Days · Tout sèks · Mizajou Sep 4, 2026 · NCT02532452A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT07544589A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
Ap rekriteFaz 3
2 Months · Tout sèks · Mizajou Aug 10, 2026 · NCT07387367R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Ap rekriteFaz 1
3 Months – 26 Years · Tout sèks · Mizajou Jul 30, 2026 · NCT06926894TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Ap rekriteFaz 1
Tout laj · Tout sèks · Mizajou Jun 11, 2026 · NCT04013802R-MVST Cells for Treatment of Viral Infections
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 10, 2026 · NCT05183490Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Apr 21, 2026 · NCT03878121Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation
Ap rekriteFaz 2
Jiska laj 18 · Tout sèks · Mizajou Feb 23, 2026 · NCT05664126Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
Ap rekriteFaz 1/2
1 Month – 65 Years · Tout sèks · Mizajou Aug 14, 2025 · NCT06909110Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
Ap rekriteFaz 2
1 Month – 79 Years · Tout sèks · Mizajou Aug 8, 2025 · NCT03266627Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections
Ap rekriteFaz 1/2
Jiska laj 60 · Tout sèks · Mizajou May 13, 2025 · NCT04722029Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.